2 reports of this reaction
2.0% of all INFANTS IBUPROFEN reports
#10 most reported adverse reaction
NASAL CONGESTION is the #10 most commonly reported adverse reaction for INFANTS IBUPROFEN, manufactured by Aurohealth LLC. There are 2 FDA adverse event reports linking INFANTS IBUPROFEN to NASAL CONGESTION. This represents approximately 2.0% of all 101 adverse event reports for this drug.
Patients taking INFANTS IBUPROFEN who experience nasal congestion should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NASAL CONGESTION is a less commonly reported adverse event for INFANTS IBUPROFEN, but still significant enough to appear in the safety profile.
In addition to nasal congestion, the following adverse reactions have been reported for INFANTS IBUPROFEN:
The following drugs have also been linked to nasal congestion in FDA adverse event reports:
NASAL CONGESTION has been reported as an adverse event in 2 FDA reports for INFANTS IBUPROFEN. This does not prove causation, but indicates an association observed in post-market surveillance data.
NASAL CONGESTION accounts for approximately 2.0% of all adverse event reports for INFANTS IBUPROFEN, making it a notable side effect.
If you experience nasal congestion while taking INFANTS IBUPROFEN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.